Novartis reports positive results from Phase III ALIGN trial for IgAN

Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia slows kidney function decline versus placebo in adults with IgAN. The trial enrolled 340 patients and assessed Vanrafia’s safety, tolerability, and efficacy over 132 weeks. The data provided specific evidence regarding Vanrafia’s impact on eGFR and urinary protein reduction. Credit: sasirin pamai / Shutterstock.com. Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function decline versus placebo in adults with IgA nephropathy (IgAN). The 2.5-year findings were published in The Lancet and showed a case at the European…

Source: Clinical Trials Arena